Powered by the AI platform Geneyx Analysis, the AI-based platform from Geneyx is the premier choice for genetic labs, hospitals, translational researchers, and early target discovery scientists. Its AI-based solutions reduce turn-around times and provide biomedical interpretation capabilities across more than 18% of the genome and 10x protein-coding scope. Geneyx is continuously developing new solutions to improve the range and accuracy of its interpretation capabilities.
Its software combines clinical and genetic data and creates a secure platform for managing and analyzing this data. Geneyx's technology allows researchers to quickly identify genetic variants and discover new diseases that are otherwise undiagnosed. It also enables secure storage of clinical data and a greater revenue potential for genetics researchers. To learn more, visit Geneyx's website or contact its representatives at info@geneyx.
Accenture has made a strategic investment in Israeli genomic analysis software developer Geneyx Genomex Ltd. Geneyx uses AI to guide digital insights by harnessing genetic data. Its AI-based analysis platform simplifies diagnostics and accelerates the development of targeted therapies. The company was recently accepted into Accenture Ventures' Project Spotlight, which offers a unique opportunity to gain access to the domain expertise of the Global 2000. The new company is aiming to use Accenture's 55 million de-identified patient electronic medical records as a platform for its platform.
Codified by Codified Genomics allows researchers to quickly understand genetic variations and interpret genomic variants. Mastermind is integrated into Codified. Breakthrough Genomics has also developed AION, which improves interpretation of genetic variants in clinical tests. Both products incorporate Mastermind Data. With these new offerings, the Genome Browser and eVai Variant Interpretation platform have merged their strengths. These three technologies empower researchers in NGS analysis and generate case reports automatically.